Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia

Completed · Phase 3

Conditions studied: Neoplasms, Thrombocytopenia, Multiple Myeloma, Lymphoma, Malignant

In brief

Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has demonstrated the ability to increase platelet counts. This study will test the safety and efficacy of this investigational drug in the prevention of thrombocytopenia in patients with solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support.

Key facts

Study ID: NCT00037791
Run by: Pfizer
People needed: 180
Starts: 1999-12-01
Expected to finish: 2002-09-01
Last updated by the study team: 2006-11-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have solid tumors, lymphomas or multiple myeloma who are receiving myelosuppressive treatment regimens requiring platelet transfusion support

You may not qualify if…

Patients must not have active bleeding (exclusions do apply) or history of platelet disorder

Where it is running

Pfizer Investigational Site — Berkeley, California, United States
Pfizer Investigational Site — La Jolla, California, United States
Pfizer Investigational Site — Los Angeles, California, United States
Pfizer Investigational Site — Los Angeles, California, United States
Pfizer Investigational Site — New Orleans, Louisiana, United States
Pfizer Investigational Site — Houston, Texas, United States
Pfizer Investigational Site — Buenos Aires, Buenos Aires F.D., Argentina
Pfizer Investigational Site — Buenos Aires, Buenos Aires F.D., Argentina
Pfizer Investigational Site — Mexico City, Mexico City, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.